Etiket: GTAEXS617
First patient in phase I/II "ELUCIDATE” study evaluating GTAEXS617 in advanced solid tumors
Exscientia plc (Nasdaq: EXAI) announced today that it has enrolled the first patient in its Phase I/II “ELUCIDATE” (GTAEXS617-001) study evaluating GTAEXS617 (‘617), a precision engineered CDK7 inhibitor for the…